keyword
https://read.qxmd.com/read/38639475/heparan-sulfates-and-heparan-sulfate-proteoglycans-in-hematopoiesis
#1
JOURNAL ARTICLE
Richard T Piszczatowski, Hannes Buelow, Ulrich Steidl
From signaling mediators in stem cells, to markers of differentiation and lineage commitment, to facilitators for the entry of viruses like HIV-1, cell surface heparan sulfate (HS) glycans with their distinct modification patterns play important roles in hematopoietic biology. In this review, we provide an overview of the importance of HS and the proteoglycans (HSPGs) to which they are attached, within the major cellular subtypes of the hematopoietic system. We summarize the roles of HSPGs, HS, and HS modifications within each main hematopoietic cell lineage of both myeloid and lymphoid arms...
March 22, 2024: Blood
https://read.qxmd.com/read/38402617/an-iron-rheostat-controls-hematopoietic-stem-cell-fate
#2
JOURNAL ARTICLE
Yun-Ruei Kao, Jiahao Chen, Rajni Kumari, Anita Ng, Aliona Zintiridou, Madhuri Tatiparthy, Yuhong Ma, Maria M Aivalioti, Deeposree Moulik, Sriram Sundaravel, Daqian Sun, Julie A Reisz, Juliane Grimm, Nuria Martinez-Lopez, Stephanie Stransky, Simone Sidoli, Ulrich Steidl, Rajat Singh, Angelo D'Alessandro, Britta Will
Mechanisms governing the maintenance of blood-producing hematopoietic stem and multipotent progenitor cells (HSPCs) are incompletely understood, particularly those regulating fate, ensuring long-term maintenance, and preventing aging-associated stem cell dysfunction. We uncovered a role for transitory free cytoplasmic iron as a rheostat for adult stem cell fate control. We found that HSPCs harbor comparatively small amounts of free iron and show the activation of a conserved molecular response to limited iron-particularly during mitosis...
February 19, 2024: Cell Stem Cell
https://read.qxmd.com/read/38376944/immunotherapy-resistant-acute-lymphoblastic-leukemia-cells-exhibit-reduced-cd19-and-cd22-expression-and-btk-pathway-dependency
#3
JOURNAL ARTICLE
Sarah Aminov, Orsi Giricz, David T Melnekoff, R Alejandro Sica, Veronika Polishchuk, Cristian Papazoglu, Bonnie Yates, Hao-Wei Wang, Srabani Sahu, Yanhua Wang, Shanisha Gordon-Mitchell, Violetta V Leshchenko, Carolina Schinke, Kith Pradhan, Srinivas Aluri, Moah Sohn, Stefan K Barta, Beamon Agarwal, Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, William Matsui, Ulrich Steidl, Joshua D Brody, Nirali N Shah, Samir Parekh, Amit Verma
While therapies targeting CD19 by antibodies, CAR-T cells and T cell engagers have improved the response rates in B-cell malignancies; the emergence of resistant cell populations with low CD19 expression can lead to relapsed disease. We developed an in vitro model of adaptive resistance facilitated by chronic exposure of leukemia cells to a CD19-immunotoxin. Single-cell (sc) RNAseq showed increase in transcriptionally distinct CD19low populations in resistant cells. Mass cytometry demonstrated that CD22 was also decreased in these CD19low resistant cells...
February 20, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/38150184/acute-lymphoblastic-leukemia-with-myeloid-mutations-is-a-high-risk-disease-associated-with-clonal-hematopoiesis
#4
JOURNAL ARTICLE
Caner Saygin, Pu Zhang, Jacob Stauber, Ibrahim Aldoss, Adam S Sperling, Lachelle D Weeks, Marlise R Luskin, Todd C Knepper, Pankhuri Wanjari, Peng Wang, Angela M Lager, Carrie Fitzpatrick, Jeremy P Segal, Mehdi Gharghabi, Sandeep Gurbuxani, Girish Venkataraman, Jason X Cheng, Bart J Eisfelder, Oliver Bohorquez, Anand A Patel, Sheethal Umesh Nagalakshmi, Savita Jayaram, Olatoyosi M Odenike, Richard A Larson, Lucy A Godley, Daniel A Arber, Christopher J Gibson, Nikhil C Munshi, Guido Marcucci, Benjamin L Ebert, John M Greally, Ulrich Steidl, Rosa Lapalombella, Bijal D Shah, Wendy Stock
Myeloid neoplasms arise from pre-existing clonal hematopoiesis (CH), however the role of CH in pathogenesis of ALL is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of these clones expanded over time to manifest as dominant clones in ALL...
December 27, 2023: Blood cancer discovery
https://read.qxmd.com/read/38024242/gliomatosis-cerebri-gc-growth-pattern-a-single-center-analysis-of-clinical-histological-and-molecular-characteristics-of-gc-and-non-gc-glioblastoma
#5
JOURNAL ARTICLE
Iris Divé, Katharina J Weber, Tabea I Hartung, Eike Steidl, Marlies Wagner, Elke Hattingen, Kea Franz, Emmanouil Fokas, Michael W Ronellenfitsch, Ulrich Herrlinger, Patrick N Harter, Joachim P Steinbach
BACKGROUND: The biological understanding of glioblastoma (GB) with gliomatosis cerebri (GC) pattern is poor due to the absence of GC-specific studies. Here, we aimed to identify molecular or clinical parameters that drive GC growth. METHODS: From our methylome database of IDH (isocitrate dehydrogenase)-wildtype GB, we identified 158 non-GC and 65 GC cases. GC cases were subdivided into diffuse-infiltrative (subtype 1), multifocal (subtype 2), or tumors with 1 solid mass (subtype 3)...
2023: Neuro-oncology advances
https://read.qxmd.com/read/37961493/haematopoietic-stem-cell-numbers-are-not-solely-determined-by-niche-availability
#6
Shoichiro Takeishi, Tony Marchand, Wade R Koba, Daniel K Borger, Chunliang Xu, Chandan Guha, Aviv Bergman, Paul S Frenette, Kira Gritsman, Ulrich Steidl
Haematopoietic stem cells (HSCs) reside in specialized microenvironments, also referred to as niches, and it has been widely believed that HSC numbers are determined by the niche size alone 1-5 . However, the vast excess of the number of niche cells over that of HSCs raises questions about this model. We initially established a mathematical model of niche availability and occupancy, which predicted that HSC numbers are restricted at both systemic and local levels. To address this question experimentally, we developed a femoral bone transplantation system, enabling us to increase the number of available HSC niches...
October 29, 2023: bioRxiv
https://read.qxmd.com/read/37745570/prenatal-vitamin-d-deficiency-alters-immune-cell-proportions-of-young-adult-offspring-through-alteration-of-long-term-stem-cell-fates
#7
Koki Ueda, Shu Shien Chin, Noriko Sato, Miyu Nishikawa, Kaori Yasuda, Naoyuki Miyasaka, Betelehem Solomon Bera, Laurent Chorro, Reanna Doña-Termine, Wade R Koba, David Reynolds, Ulrich G Steidl, Gregoire Lauvau, John M Greally, Masako Suzuki
Vitamin D deficiency is a common deficiency worldwide, particularly among women of reproductive age. During pregnancy, it increases the risk of immune-related diseases in offspring later in life. However, exactly how the body remembers exposure to an adverse environment during development is poorly understood. Herein, we explore the effects of prenatal vitamin D deficiency on immune cell proportions in offspring using vitamin D deficient mice established by dietary manipulation. We show that prenatal vitamin D deficiency alters immune cell proportions in offspring by changing the transcriptional properties of genes downstream of vitamin D receptor signaling in hematopoietic stem and progenitor cells of both the fetus and adults...
September 13, 2023: bioRxiv
https://read.qxmd.com/read/37642684/-not-available
#8
Ulrich K Fr Witzsch, Angelika Borkowetz, Thomas Enzmann, Severin Rodler, Sami-Ramzi Leyh-Bannurah, Tillmann Loch, Hendrik Borgmann, Oliver Steidle
No abstract text is available yet for this article.
August 29, 2023: Urologie
https://read.qxmd.com/read/37606658/-digitalization-in-urology-challenge-and-opportunity
#9
REVIEW
Ulrich K Fr Witzsch, Angelika Borkowetz, Thomas Enzmann, Severin Rodler, Sami-Ramzi Leyh-Bannurah, Tilmann Loch, Hendrik Borgmann, Oliver Steidle
Digitalization is changing medicine. In Germany these changes are not highly accepted yet. Medical pathways should be supported and become safer by digital transformation. Furthermore, artificial intelligence (AI) applications are increasingly used in medicine. Only time will tell whether these will decrease the workload and make patient treatment easier, while increasing precision and individualization.. Urology must accept the upcoming new challenges. This can best be done by participating in the development...
August 22, 2023: Urologie
https://read.qxmd.com/read/37467070/role-of-il8-in-myeloid-malignancies
#10
JOURNAL ARTICLE
Nandini Ramachandra, Malini Gupta, Leya Schwartz, Tihomira Todorova, Aditi Shastri, Britta Will, Ulrich Steidl, Amit Verma
Aberrant overexpression of Interleukin-8 (IL8) has been reported in Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms (MPNs) and other myeloid malignancies. IL8 (CXCL8) is a CXC chemokine that is secreted by aberrant hematopoietic stem and progenitors as well as other cells in the tumor microenvironment. IL8 can bind to CXCR1/CXCR2 receptors and activate oncogenic signaling pathways, and also increase the recruitment of myeloid derived suppressor cells to the tumor microenvironment...
July 19, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37398007/ribosomal-protein-control-of-hematopoietic-stem-cell-transformation-through-direct-non-canonical-regulation-of-metabolism
#11
Bryan Harris, Dinesh K Singh, Monika Verma, Shawn P Fahl, Michele Rhodes, Shanna R Sprinkle, Minshi Wang, Yong Zhang, Jaqueline Perrigoue, Rachel Kessel, Suraj Peri, Joshua West, Orsi Giricz, Jacqueline Boultwood, Andrea Pellagatti, K H Ramesh, Cristina Montagna, Kith Pradhan, Jeffrey W Tyner, Brian K Kennedy, Michael Holinstat, Ulrich Steidl, Stephen Sykes, Amit Verma, David L Wiest
UNLABELLED: We report here that expression of the ribosomal protein, RPL22, is frequently reduced in human myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML); reduced RPL22 expression is associated with worse outcomes. Mice null for Rpl22 display characteristics of an MDS-like syndrome and develop leukemia at an accelerated rate. Rpl22-deficient mice also display enhanced hematopoietic stem cell (HSC) self-renewal and obstructed differentiation potential, which arises not from reduced protein synthesis but from increased expression of the Rpl22 target, ALOX12, an upstream regulator of fatty acid oxidation (FAO)...
June 1, 2023: bioRxiv
https://read.qxmd.com/read/37352101/dna-selection-by-the-master-transcription-factor-pu-1
#12
JOURNAL ARTICLE
J Ross Terrell, Samuel J Taylor, Amelia L Schneider, Yue Lu, Tyler N Vernon, Suela Xhani, Ryan H Gumpper, Ming Luo, W David Wilson, Ulrich Steidl, Gregory M K Poon
The master transcriptional regulator PU.1/Spi-1 engages DNA sites with affinities spanning multiple orders of magnitude. To elucidate this remarkable plasticity, we have characterized 22 high-resolution co-crystallographic PU.1/DNA complexes across the addressable affinity range in myeloid gene transactivation. Over a purine-rich core (such as 5'-GGAA-3') flanked by variable sequences, affinity is negotiated by direct readout on the 5' flank via a critical glutamine (Q226) sidechain and by indirect readout on the 3' flank by sequence-dependent helical flexibility...
June 22, 2023: Cell Reports
https://read.qxmd.com/read/36918485/outcome-of-stem-cell-transplantation-in-htlv-1-associated-north-american-adult-t-cell-leukemia-lymphoma
#13
JOURNAL ARTICLE
Abdul-Hamid Bazarbachi, Daniel Reef, Hiba Narvel, Riya Patel, Rama Al Hamed, Sindhu Vikash, Karun Neupane, Eleftheria Atalla, Astha Thakkar, Shafia Rahman, Urvi Shah, Diego Adrianzen-Herrera, Ryann Quinn, Sumaira Zareef, Emma Rabinovich, Alyssa De Castro, Felisha Joseph, Kailyn Gillick, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Latoya Townsend-Nugent, Michelly Abreu, Nicole Chambers, Richard Elkind, Yang Shi, Yanhua Wang, Olga Derman, Kira Gritsman, Ulrich Steidl, Mendel Goldfinger, Noah Kornblum, Aditi Shastri, Ioannis Mantzaris, Liza Bachier-Rodriguez, Nishi Shah, Dennis Cooper, Amit Verma, Bihui Hilda Ye, Murali Janakiram, Roberto Alejandro Sica
Adult T-cell leukemia/lymphoma (ATLL) remains challenging to treat and has dismal outcome. Allogeneic stem-cell transplantation (allo-SCT) has promising results, but data remain scarce. In this single-center retrospective analysis of 100 patients with ATLL from north America (67 acute, 22 lymphomatous), 17 underwent allo-SCT and 5 autologous SCT (ASCT), with a median follow-up of 65 months. Post-transplant 3-years relapse incidence (RI) and non-relapse mortality (NRM) were 51% and 37%, respectively, and 3-year progression-free survival (PFS) and overall survival (OS) were 31% and 35%, respectively...
March 15, 2023: Clinical hematology international
https://read.qxmd.com/read/36865338/glutaminase-inhibition-in-combination-with-azacytidine-in-myelodysplastic-syndromes-clinical-efficacy-and-correlative-analyses
#14
Marina Konopleva, Courtney DiNardo, Tushar Bhagat, Natalia Baran, Alessia Lodi, Kapil Saxena, Tianyu Cai, Xiaoping Su, Anna Skwarska, Veronica Guerra, Vinitha Kuruvilla, Sergej Konoplev, Shanisha Gordon-Mitchell, Kith Pradhan, Srinivas Aluri, Meghan Collins, Shannon Sweeney, Jonathan Busquet, Atul Rathore, Qing Deng, Michael Green, Steven Grant, Susan Demo, Gaurav Choudhary, Srabani Sahu, Beamon Agarwal, Mason Spodek, Victor Thiruthuvanathan, Britta Will, Ulrich Steidl, George Tippett, Jan Burger, Gautam Borthakur, Elias Jabbour, Naveen Pemmaraju, Tapan Kadia, Steven Kornblau, Naval Daver, Kiran Naqvi, Nicholas Short, Guillermo Garcia-Manero, Stefano Tiziani, Amit Verma
Malignancies can become reliant on glutamine as an alternative energy source and as a facilitator of aberrant DNA methylation, thus implicating glutaminase (GLS) as a potential therapeutic target. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective GLS inhibitor, when combined with azacytidine (AZA), in vitro and in vivo , followed by a phase Ib/II study of the combination in patients with advanced MDS. Treatment with telaglenastat/AZA led to an ORR of 70% with CR/mCRs in 53% patients and a median overall survival of 11...
February 23, 2023: Research Square
https://read.qxmd.com/read/36812307/pi3-kinase-deletion-promotes-myelodysplasia-by-dysregulating-autophagy-in-hematopoietic-stem-cells
#15
JOURNAL ARTICLE
Kristina Ames, Imit Kaur, Yang Shi, Meng M Tong, Taneisha Sinclair, Shayda Hemmati, Shira G Glushakow-Smith, Ellen Tein, Lindsay Gurska, Ulrich Steidl, Robert Dubin, Jidong Shan, Cristina Montagna, Kith Pradhan, Amit Verma, Kira Gritsman
Myelodysplastic syndrome (MDS) is a clonal malignancy arising in hematopoietic stem cells (HSCs). The mechanisms of MDS initiation in HSCs are still poorly understood. The phosphatidylinositol 3-kinase (PI3K)/AKT pathway is frequently activated in acute myeloid leukemia, but in MDS, PI3K/AKT is often down-regulated. To determine whether PI3K down-regulation can perturb HSC function, we generated a triple knockout (TKO) mouse model with Pik3ca , Pik3cb , and Pik3cd deletion in hematopoietic cells. Unexpectedly, PI3K deficiency caused cytopenias, decreased survival, and multilineage dysplasia with chromosomal abnormalities, consistent with MDS initiation...
February 22, 2023: Science Advances
https://read.qxmd.com/read/36255372/lenalidomide-and-eltrombopag-for-treatment-of-low-or-intermediate-risk-myelodysplastic-syndrome-result-of-a-phase-ii-clinical-trial
#16
MULTICENTER STUDY
Jesus D Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, Kith Pradhan, Mimi Kim, Ioannis Mantzaris, R Alejandro Sica, Nishi Shah, Mendel Goldfinger, Noah Kornblum, Kira Gritsman, Ira Braunschweig, Ulrich Steidl, Britta Will, Aditi Shastri, Amit Verma
PURPOSE: Thrombocytopenia is a serious complication of myelodysplastic syndromes (MDS) associated with an increased bleeding risk and worse prognosis. Eltrombopag (ELT), a thrombopoietin receptor agonist, can increase platelet counts and reverse anti-megakaryopoietic effects of lenalidomide (LEN) in preclinical studies. We hypothesized ELT would reduce the incidence of thrombocytopenia in MDS. PATIENTS AND METHODS: We conducted a Phase II multicenter trial of ELT and LEN in adult patients with low- or intermediate-1-risk MDS with symptomatic or transfusion-dependent anemia or thrombocytopenia (NCT01772420)...
January 4, 2023: Clinical Cancer Research
https://read.qxmd.com/read/36066492/a-glycan-based-approach-to-cell-characterization-and-isolation-hematopoiesis-as-a-paradigm
#17
JOURNAL ARTICLE
Richard T Piszczatowski, Emily Schwenger, Sriram Sundaravel, Catarina M Stein, Yang Liu, Pamela Stanley, Amit Verma, Deyou Zheng, Ronald D Seidel, Steven C Almo, Robert A Townley, Hannes E Bülow, Ulrich Steidl
Cell surfaces display a wide array of molecules that confer identity. While flow cytometry and cluster of differentiation (CD) markers have revolutionized cell characterization and purification, functionally heterogeneous cellular subtypes remain unresolvable by the CD marker system alone. Using hematopoietic lineages as a paradigm, we leverage the extraordinary molecular diversity of heparan sulfate (HS) glycans to establish cellular "glycotypes" by utilizing a panel of anti-HS single-chain variable fragment antibodies (scFvs)...
November 7, 2022: Journal of Experimental Medicine
https://read.qxmd.com/read/36040792/activation-of-targetable-inflammatory-immune-signaling-is-seen-in-myelodysplastic-syndromes-with-sf3b1-mutations
#18
JOURNAL ARTICLE
Gaurav S Choudhary, Andrea Pellagatti, Bogos Agianian, Molly A Smith, Tushar D Bhagat, Shanisha Gordon-Mitchell, Srabani Sahu, Sanjay Pandey, Nishi Shah, Srinivas Aluri, Ritesh Aggarwal, Sarah Aminov, Leya Schwartz, Violetta Steeples, Robert N Booher, Murali Ramachandra, Maria Samson, Milagros Carbajal, Kith Pradhan, Teresa V Bowman, Manoj M Pillai, Britta Will, Amittha Wickrema, Aditi Shastri, Robert K Bradley, Robert E Martell, Ulrich G Steidl, Evripidis Gavathiotis, Jacqueline Boultwood, Daniel T Starczynowski, Amit Verma
Background: Mutations in the SF3B1 splicing factor are commonly seen in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), yet the specific oncogenic pathways activated by mis-splicing have not been fully elucidated. Inflammatory immune pathways have been shown to play roles in the pathogenesis of MDS, though the exact mechanisms of their activation in splicing mutant cases are not well understood. Methods: RNA-seq data from SF3B1 mutant samples was analyzed and functional roles of interleukin-1 receptor-associated kinase 4 ( IRAK4) isoforms were determined...
August 30, 2022: ELife
https://read.qxmd.com/read/35883108/correction-innate-immune-mediator-interleukin-1-receptor-accessory-protein-il1rap-is-expressed-and-pro-tumorigenic-in-pancreatic-cancer
#19
Yang Zhang, Xiaoyi Chen, Huamin Wang, Shanisha Gordon-Mitchell, Srabani Sahu, Tushar D Bhagat, Gaurav Choudhary, Srinivas Aluri, Kith Pradhan, Plabani Sahu, Milagros Carbajal, Hui Zhang, Beamon Agarwal, Aditi Shastri, Robert Martell, Daniel Starczynowski, Ulrich Steidl, Anirban Maitra, Amit Verma
No abstract text is available yet for this article.
July 26, 2022: Journal of Hematology & Oncology
https://read.qxmd.com/read/35771633/hsmotifdiscover-identification-of-motifs-in-sequences-composed-of-non-single-letter-elements
#20
JOURNAL ARTICLE
Vinod Kumar Singh, Rohan Misra, Steven C Almo, Ulrich G Steidl, Hannes E Bülow, Deyou Zheng
SUMMARY: The functional sub-string(s) of a biopolymer sequence defines the specificity of its interaction with other biomolecules and is often referred to as motifs. Computational algorithms and software have been broadly developed for finding such motifs in sequences in which the individual elements are single characters, such as those in DNA and protein sequences. However, there are more complex scenarios where the motifs exist in non-single-letter contexts, for example, preferred patterns of chemical modifications on proteins, DNAs, RNAs, or polysaccharides...
June 30, 2022: Bioinformatics
keyword
keyword
85082
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.